2020
DOI: 10.1007/s00253-020-11014-y
|View full text |Cite
|
Sign up to set email alerts
|

Development of recombinant human granulocyte colony-stimulating factor (nartograstim) production process in Escherichia coli compatible with industrial scale and with no antibiotics in the culture medium

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

0
2
0

Year Published

2021
2021
2025
2025

Publication Types

Select...
3
1

Relationship

0
4

Authors

Journals

citations
Cited by 4 publications
(2 citation statements)
references
References 57 publications
0
2
0
Order By: Relevance
“…In the biopharmaceutical industry, E. coli is regarded as the first‐choice microorganism for the production of recombinant nonglycosylated proteins. However, when using E. coli for the industrial production of therapeutic molecules, regulatory quality aspects should be considered 92,93,96–104 . Although some E. coli strains have the ability to produce a toxin, most of them are harmless and even useful mainly in recombinant protein production.…”
Section: Expression Hostsmentioning
confidence: 99%
See 1 more Smart Citation
“…In the biopharmaceutical industry, E. coli is regarded as the first‐choice microorganism for the production of recombinant nonglycosylated proteins. However, when using E. coli for the industrial production of therapeutic molecules, regulatory quality aspects should be considered 92,93,96–104 . Although some E. coli strains have the ability to produce a toxin, most of them are harmless and even useful mainly in recombinant protein production.…”
Section: Expression Hostsmentioning
confidence: 99%
“…However, when using E. coli for the industrial production of therapeutic molecules, regulatory quality aspects should be considered. 92,93,[96][97][98][99][100][101][102][103][104] Although some E. coli strains have the ability to produce a toxin, most of them are harmless and even useful mainly in recombinant protein production. Maksum et al produced β-galactosidase in a wildtype E. coli B130 strain.…”
Section: Hosts For the Expression Of Bacterial β-Galactosidases Genementioning
confidence: 99%